MRFR

  Regadenoson, a pharmacologic stress agent used in myocardial perfusion imaging (MPI) for patients unable to undergo adequate exercise stress, has seen significant growth in its market due to its clinical efficacy and safety profile. The increasing prevalence of cardiovascular diseases, coupled with the rising geriatric population, has driven the demand for advanced diagnostic tools, including MPI, thereby propelling the  Regadenoson market   forward. Market Drivers and Trends Rising Cardiovascular Diseases:  Cardiovascular diseases remain a leading cause of mortality worldwide. The World Health Organization (WHO) reports that approximately 17.9 million people die from cardiovascular diseases each year. This alarming statistic underscores the need for effective diagnostic and treatment modalities, where Regadenoson plays a crucial role. As a selective A2A adenosine receptor agonist, it induces coronary vasodilation, enhancing the detection of coronary artery disease...